title: A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
abstract: The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.
authors.affiliation: University Department, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: N M
authors.initials: NM
authors.lastname: Bleehen
authors.forename: A H
authors.initials: AH
authors.lastname: Calvert
authors.forename: S M
authors.initials: SM
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Harper
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: I
authors.initials: I
authors.lastname: Judson
authors.forename: M
authors.initials: M
authors.lastname: Brampton
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D014226:Triazenes / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014226:Triazenes; C030838:1-(4-carboxyphenyl)-3,3-dimethyltriazene